Robin Rudd

3.7k citations

50 papers · 2.4k indexed · h-index 22

Impact in

Pulmonary and Respiratory Medicine top 1%
- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
- Lung Cancer Treatments and Mutations
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Lung Cancer Diagnosis and Treatment
Oncology top 5%
- Lung Cancer Research Studies

Papers in ⓘ

Pulmonary and Respiratory Medicine 39
- Occupational and environmental lung diseases 19
- Pleural and Pulmonary Diseases 15
- Lung Cancer Treatments and Mutations 15
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis 9
- Lung Cancer Diagnosis and Treatment 8
Oncology 18
- Lung Cancer Research Studies 15

Co-authors: Stephen Spiro (13 shared papers)M. Beckles (2 shared papers)Gene Colice (2 shared papers)Jeremy Steele (17 shared papers)Dean A. Fennell (12 shared papers)Jonathan Shamash (11 shared papers)Nicole H. Gower (12 shared papers)Marie T. Evans (9 shared papers)
Journals: Lung Cancer (11 papers)Journal of Clinical Oncology (6 papers)European Journal of Cancer (3 papers)Journal of Thoracic Oncology (2 papers)Cancer Chemotherapy and Pharmacology (2 papers)
Partner nations: United Kingdom United States Ireland

In The Last Decade

Robin Rudd

49 papers receiving 2.3k citations

Peers

Countries citing papers authored by Robin Rudd

Since Specialization

Citations

This map shows the geographic impact of Robin Rudd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Rudd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Rudd more than expected).

Fields of papers citing papers by Robin Rudd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Rudd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Rudd. The network helps show where Robin Rudd may publish in the future.

Co-authors

The 25 scholars most cited alongside Robin Rudd, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robin Rudd Line = papers co-authored together Robin Rudd links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 50 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data Journal of Clinical Oncology ·Antônio Rossi, Massimo Di Maïo, Paolo Chiodini, Robin Rudd, Hiroaki Okamoto, Dimosthenis Skarlos, Martin Früh, Wendi Qian, Tomohide Tamura, E. Samantas, Taro Shibata, Francesco Perrone, Ciro Gallo, Cesare Gridelli, Olga Martelli, Siow Ming Lee	2012	381
2	The Physiologic Evaluation of Patients With Lung Cancer Being Considered for Resectional Surgery* CHEST Journal ·M. Beckles, Stephen Spiro, Gene Colice, Robin Rudd	2003	237
3	Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial The Lancet ·Martin F. Muers, Richard Stephens, P.M. Fisher, Liz Darlison, C M B Higgs, Erica Lowry, Andrew G. Nicholson, Mary O’Brien, Michael Peake, Robin Rudd, M. Snee, Jeremy Steele, D.J. Girling, Matthew Nankivell, Cheryl Pugh, Mahesh Parmar	2008	177
4	Phase II Study of Vinorelbine in Patients With Malignant Pleural Mesothelioma Journal of Clinical Oncology ·Jeremy Steele, Jonathan Shamash, Marie T. Evans, Nicole H. Gower, Marc Tischkowitz, Robin Rudd	2000	152
5	In vivo Loss of Expression of Argininosuccinate Synthetase in Malignant Pleural Mesothelioma Is a Biomarker for Susceptibility to Arginine Depletion Clinical Cancer Research ·Peter W. Szlosarek, Astero Klabatsa, A. Pallaska, Michael Sheaff, Paul Smith, Tim Crook, Matthew J. Grimshaw, Jeremy Steele, Robin Rudd, Frances R. Balkwill, Dean A. Fennell	2006	150
6	Initial Evaluation of the Patient With Lung Cancer* CHEST Journal ·M. Beckles, Stephen Spiro, Gene Colice, Robin Rudd	2003	142
7	First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial The Lancet Oncology ·Siow Ming Lee, Iftekhar Khan, Sunil Upadhyay, C. Lewanski, Stephen Falk, G. Skailes, Ernie Marshall, Penella J. Woll, M. Hatton, Rohit Lal, Richard C. Jones, Elizabeth Toy, David Chao, Gary Middleton, Sue Bulley, Yenting Ngai, Robin Rudd, Allan Hackshaw, Chris Boshoff	2012	133
8	Early Compared With Late Radiotherapy in Combined Modality Treatment for Limited Disease Small-Cell Lung Cancer: A London Lung Cancer Group Multicenter Randomized Clinical Trial and Meta-Analysis Journal of Clinical Oncology ·Stephen Spiro, Lindsay E. James, Robin Rudd, Colin Trask, Jeffrey Tobias, M. Snee, David Gilligan, Philip A. Murray, M C Ruiz de Elvira, Katy M. O'Donnell, Nicole H. Gower, Peter Harper, Allan Hackshaw	2006	124
9	The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma Lung Cancer ·Justin Stebbing, Thomas Powles, Kirsty McPherson, Jonathan Shamash, Paula Wells, Michael Sheaff, Sarah Slater, Robin Rudd, Dean A. Fennell, Jeremy Steele	2008	108
10	Anti-angiogenic Therapy Using Thalidomide Combined With Chemotherapy in Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial JNCI Journal of the National Cancer Institute ·Siow Ming Lee, Penella J. Woll, Robin Rudd, David Ferry, Mary O’Brien, Gary Middleton, Stephen Spiro, Lindsay E. James, Kulsam Ali, Mark Jitlal, Allan Hackshaw	2009	95
11	Statistical Validation of the EORTC Prognostic Model for Malignant Pleural Mesothelioma Based on Three Consecutive Phase II Trials Journal of Clinical Oncology ·Dean A. Fennell, Amit Parmar, Jonathan Shamash, Marie T. Evans, Michael Sheaff, Richard Sylvester, Kevin Dhaliwal, Nicole H. Gower, Jeremy Steele, Robin Rudd	2004	91
12	Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development The Lancet Oncology ·Dean A. Fennell, Robin Rudd	2004	66
13	Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non–Small-Cell Lung Cancer Journal of Clinical Oncology ·Siow Ming Lee, Robin Rudd, Penella J. Woll, Christian H. Ottensmeier, David Gilligan, Allan Price, Stephen Spiro, Nicole H. Gower, Mark Jitlal, Allan Hackshaw	2009	50
14	Prognostic factors in mesothelioma Lung Cancer ·Jeremy Steele, Astero Klabatsa, Dean A. Fennell, A. Pallaska, Mike Sheaff, Marie T. Evans, Jonathan Shamash, Robin Rudd	2005	48
15	Phase II trial of vinorelbine and oxaliplatin as first-line therapy in malignant pleural mesothelioma Lung Cancer ·Dean A. Fennell, Jeremy Steele, Jonathan Shamash, Michael Sheaff, Marie T. Evans, T.I. Goonewardene, Maria Nyström, N.H. Gower, Robin Rudd	2004	40
16	Efficacy and safety of first‐ or second‐line irinotecan, cisplatin, and mitomycin in mesothelioma Cancer ·Dean A. Fennell, Jeremy Steele, Jonathan Shamash, Marie T. Evans, Paula Wells, Michael Sheaff, Robin Rudd, Justin Stebbing	2006	37
17	Inhibition of exercise-induced asthma by an orally absorbed mast cell stabilizer (M & B 22,948) British Journal of Diseases of the Chest ·Robin Rudd, Andrew Gellert, Peter R. Studdy, D M Geddes	1983	34
18	Phase II study of Edatrexate in stage III and IV non-small-cell lung cancer Cancer Chemotherapy and Pharmacology ·Robert L. Souhami, Robin Rudd, Stephen Spiro, Ruth Allen, Peter Lamond, Peter Harper	1992	30
19	Reduced pulmonary microvascular permeability in severe chronic left heart failure American Heart Journal ·Simon Davies, James Bailey, Jennifer Keegan, R Balcon, Robin Rudd, D P Lipkin	1992	30
20	O-179 The Big Lung Trial (BLT): Determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting Lung Cancer ·David Waller, David Fairlamb, Nicole H. Gower, Robert Milroy, Michael Peake, Robin Rudd, Stephen Spiro, Richard Stephens	2003	29

About Robin Rudd

Robin Rudd is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Epidemiology, Biotechnology and Molecular Biology, having authored 50 papers that have together received 2.4k indexed citations. Recurring topics across this work include Occupational and environmental lung diseases (19 papers), Pleural and Pulmonary Diseases (15 papers), Lung Cancer Research Studies (15 papers), Lung Cancer Treatments and Mutations (15 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (9 papers), Lung Cancer Diagnosis and Treatment (8 papers), Cancer Research and Treatments (6 papers) and Neuroendocrine Tumor Research Advances (6 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.6k citations), Oncology (930 citations), Biotechnology (176 citations), Epidemiology (476 citations) and Cancer Research (150 citations). Robin Rudd has collaborated with scholars based in United Kingdom, United States and Ireland. Frequent co-authors include Stephen Spiro, M. Beckles, Gene Colice, Jeremy Steele, Dean A. Fennell, Jonathan Shamash, Nicole H. Gower, Marie T. Evans, Siow Ming Lee and Michael Sheaff. Their work appears in journals such as Lung Cancer, Journal of Clinical Oncology, European Journal of Cancer, Journal of Thoracic Oncology and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact